Baxter to acquire Immuno in $715 million deal
This article was originally published in Clinica
Baxter International is strengthening its biotech business with the acquisition of Swiss-based Immuno International. A staged purchase over three years will cost Baxter around $715 million in cash. Both companies' boards have sanctioned the deal, but approval of anti-trust authorities in Europe and the US is still required.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.